Significance of low level infliximab in the absence of anti-infliximab antibodies

AIM: To evaluate the prevalence of double negative (DN) sera and the mechanisms responsible for DN status. METHODS: Sera of inflammatory bowel disease patients treated with infliximab (IFX) were tested for drug/antibodies to infliximab (ATI) trough levels and the proportion of DN results was compare...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:World J Gastroenterol
Auteurs principaux: Ungar, Bella, Anafy, Adi, Yanai, Henit, Ron, Yulia, Yavzori, Miri, Picard, Orit, Fudim, Ella, Loebstein, Ronen, Kopylov, Uri, Chowers, Yehuda, Dotan, Iris, Eliakim, Rami, Ben-Horin, Shomron
Format: Artigo
Langue:Inglês
Publié: Baishideng Publishing Group Inc 2015
Sujets:
Observational Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323470/
https://ncbi.nlm.nih.gov/pubmed/25684959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i6.1907
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires